PVLA vs SGP: fair value comparison
Palvella Therapeutics, Inc. and SpyGlass Pharma, Inc. · Updated 2026-10-19
PVLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SGP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PVLA currently ranks higher by quality score.
| PVLA | SGP | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $120.30 | $24.00 |
| 12-month range | $70.43–$158.13 | $18.32–$26.86 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #262 of 301 Healthcare | #264 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: PVLA fair value analysis · SGP fair value analysis